Methylation of microRNA-34 and microRNA-124 Family in Korean Patients with Non-Small Cell Lung Cancers
분야
의약학 > 내과학
저자
이신엽 , 이수만 , 김동선 , 손지웅 , 유승수 , 이재희 , 차승익 , 김창호 , 박재용
발행기관
대한결핵 및 호흡기학회
간행물정보
대한결핵및호흡기학회 추계학술발표초록집 2012년, 제114권 294(총1페이지)
파일형식
0y910086.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    1,000원
    적립금
    30원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    영문초록
    MicroRNA (miR)-34 and miR-124 have been demonstrated as a potential tumor suppressor in several types of cancers. Each family includes three processed miRNAs (miR-34a, miR-34b, miR-34c, miR-124-1, miR-124-2, and miR-124-3). The tran-scriptional silencing of tumor suppressor genes by CpG island promoter hypermethylation has emerged as a common hallmark. To understand the role of miR-34 and miR-124 in non-small cell lung cancer (NSCLC) and to develop a promising candidate biomarker for diagnosis and prognosis of NSCLC, we determined the methylation status of 6 miR genes in primary lung tissues using a methylation-specific PCR (MSP) and evaluated their relationship with clinicopatholgial features and survival in patients with NSCLC. The methylation frequencies of 6 miR genes were 15.1% for miR-34a, 55.9% for miR-34b/c, 25.6% for miR-124-1, 52.9% for miR-124-3 in malignant tissues. The methylation frequencies of miR-34b/c and miR-124-3 were significantly higher in squamous cell carcinomas than in adenocarcinomas. In addition, miR-34b/c methylation was frequently observed in EGFR mutation-negative adenocarcinomas compared to EGFR mutation-positive ones. However, there was no significant difference in overall survival of the total patients according to six miR genes.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일 help@reportshop.co.kr
    copyright (c) 2009 happynlife. steel All reserved.